Combining Androgen Deprivation and Immunotherapy in Prostate Cancer Treatment: A Mechanistic Approach
Due to its initial dependence on testosterone, prostate cancer patients are initially treated with androgen deprivation therapy, a form of chemical castration. However, in many cases, the cancer develops resistance to this treatment. Sipuleucel-T (Provenge), is the first live cell vaccine approved f...
Main Authors: | Johnna Barnaby, Harsh Vardhan Jain |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-07-01
|
Series: | Applied Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3417/12/14/6954 |
Similar Items
-
Standing Variations Modeling Captures Inter-Individual Heterogeneity in a Deterministic Model of Prostate Cancer Response to Combination Therapy
by: Harsh Vardhan Jain, et al.
Published: (2021-04-01) -
Neoadjuvant versus Concurrent Androgen Deprivation Therapy in Localized Prostate Cancer Treated with Radiotherapy: A Systematic Review of the Literature
by: Rodrigo Cartes, et al.
Published: (2023-06-01) -
Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer
by: Caipeng Qin, et al.
Published: (2022-11-01) -
Editorial: Immunotherapy for Prostate Cancer – turning the immunological desert into an oasis of hope
by: Christine Galustian, et al.
Published: (2022-09-01) -
Relating prostate‐specific antigen leakage with vascular tumor growth in a mathematical model of prostate cancer response to androgen deprivation
by: Johnna P. Barnaby, et al.
Published: (2021-06-01)